6 March 1899: Aspirin trademarked

Chemical company Bayer was awarded a patent for its pain-relieving acetylsalicylic acid powder, or 'Aspirin', on this day in 1899.

As early as the Ancient Egyptians, it was recognised that using the bark of the willow tree would help relieve minor aches and pains, including those caused by colds. However, it was not until 1763 that the medical community started to systematically investigate it, with the Royal Society publishing research into its role in treating fever.

The next major breakthrough came in 1828 when a professor at Munich University extracted the active ingredient from willow, named salicin. By 1876, further tests had shown that this was effective in reducing pain. During the late 19th century, salicylic acid became an increasingly used as a pain-relief drug. However, it has several unpleasant side effects, such as bleeding and nausea, which limited its use.

Chemical company Bayer set to work in 1895 to make a more palatable version of the drug. Two years later, Felix Hoffmann came up with acetylsalicylic acid. Initially, there was some scepticism about its effectiveness compared to other similar products. However, tests vindicated the new powder, which was trademarked by Bayer at 'Aspirin' on 6 March 1899. It appeared in tablet form in 1900 and became prescription-free in 1900.

By the 1950s, it would become the most widely sold painkiller. However, in 1974, research would suggest that it also plays an important role in preventing heart attacks. There is also strong evidence that it reduces the risk of cancer. At the moment, it is one of the top ten generic drugs in the world, with annual sales of around $1.64bn. However, Bayer's patent expired in 1917, meaning that generic competitors would get most of the profits.

Bayer would also lose the US rights to the name 'Aspirin' after it attempted to get around the wartime embargo on phenol, an important ingredient.

Recommended

The charts that matter: more pain for goldbugs
Economy

The charts that matter: more pain for goldbugs

Gold investors saw more disappointment this week as the yellow metal took a tumble. Here’s what’s happened to the charts that matter most to the globa…
18 Sep 2021
The new social-care levy: an unfair tax that protects the “assetocracy”
National Insurance

The new social-care levy: an unfair tax that protects the “assetocracy”

The government’s regressive social-care levy will make Britain’s tax system even more complex. Root-and-branch reform is long overdue.
18 Sep 2021
Kieran Heinemann: the history of shareholder capitalism
Investment strategy

Kieran Heinemann: the history of shareholder capitalism

Merryn talks to Kieran Heinemann, author of Playing the Market: Retail Investment and Speculation in Twentieth-Century Britain, about the history of t…
17 Sep 2021
Cryptocurrency roundup: litecoin blunder, cardano update and bitcoin mining in Laos
Bitcoin & crypto

Cryptocurrency roundup: litecoin blunder, cardano update and bitcoin mining in Laos

Saloni Sardana looks at the week’s biggest stories in the world of cryptocurrencies.
17 Sep 2021

Most Popular

The times may be changing, but don’t change how you invest
Small cap stocks

The times may be changing, but don’t change how you invest

We are living in strange times. But the basics of investing remain the same: buy fairly-priced stocks that can provide an income. And there are few be…
13 Sep 2021
Two shipping funds to buy for steady income
Investment trusts

Two shipping funds to buy for steady income

Returns from owning ships are volatile, but these two investment trusts are trying to make the sector less risky.
7 Sep 2021
Should investors be worried about stagflation?
US Economy

Should investors be worried about stagflation?

The latest US employment data has raised the ugly spectre of “stagflation” – weak growth and high inflation. John Stepek looks at what’s going on and …
6 Sep 2021